Cancer biomarkers span a broad biological spectrum, including proteins, metabolites, and nucleic acids detectable in samples such as tissue biopsies and blood. 1 At the beginning of a biomarker ...

TEM advances precision oncology as studies validate IPS, PurIST and xF+ diagnostics, highlighting stronger guidance for cancer therapy and biomarker detection.

Explore how proteomics in biomarker discovery accelerates diagnostic assay development and improves clinical validation.

However, regardless of which trial is conducted, the overfitting of data might be a substantial issue, meaning that the number of parameters in a model is too great relative to the number of samples, ...

In a recent editorial published in Current Pharmaceutical Analysis (Volume 18, Issue 6, 2022), researchers Dr. Behrouz Seyfinejad and Dr. Abolghasem Jouyban highlight the importance of method ...

Comparative Analysis of Generative Pre-Trained Transformer Models in Oncogene-Driven Non–Small Cell Lung Cancer: Introducing the Generative Artificial Intelligence Performance Score This ...

Faculty in the Medical Devices and Diagnostics Hub develop statistical methods for the design, evaluation, and validation of diagnostic tools and medical devices. Their work includes biomarker ...

Use of numares' metabolite constellation showed a stable urinary metabolic profile in the first 14 days for living donor recipients, enabling accurate early rejection detection -- Deceased donor ...

This article explores multiplexing applications in biopharma and highlights key assay development factors to consider.

Background: The Prognostic Lung Fibrosis Consortium (PROLIFIC) was formed to develop well-qualified assays suitable for use as prognostic biomarkers within the context of clinical trials for Idiopathic ...